BOSTON, Feb. 28, 2020 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a.

Q4 2019 ZIOPHARM Oncology Inc Earnings Call

BOSTON, May 27, 2020 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to.

Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced Dr. David Mauney is stepping down as President. Dr. Mauney remains a consultant to Ziopharm and will continue to help guide the Company through this transition. “It has been a tremendous privilege to serve as President of Ziopharm, and I am incredibly proud of where we are as a Company,” said Dr. Mauney.

BOSTON, Feb. 24, 2020 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2, at 4:30 p.m. ET to.

Ziopharm Oncology, Inc. (ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to Ziopharm before deducting underwriting discounts and commissions and estimated offering expenses payable by Ziopharm, are expected to be approximately $90.4 million, excluding any exercise of the underwriters’ option to purchase additional shares.

BOSTON, April 27, 2020 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to.

Ziopharm Oncology, Inc. (ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment of recurrent glioblastoma at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be conducted virtually from May 29-31, 2020. The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express TCRs to target neoantigens inside and outside hotspots for solid tumors and CAR to target CD19 for blood cancers using the Company’s “Rapid Personalized Manufacturing” to produce and release CAR-T as soon as the day after gene transfer.

It is now my pleasure to introduce your host, Chris Taylor, Investor Relations at Ziopharm. Good afternoon and welcome to the Ziopharm Oncology conference call and webcast to review results for the first quarter ended March 31, 2020.

Ziopharm Oncology (ZIOP) has been under major pressure after their recent follow-on-offering as well as the collapse in the overall market, explains biotech expert John McCamant, editor of The Medical Technology Stock Letter.

– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to.

Q1 2020 ZIOPHARM Oncology Inc Earnings Call

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Ziopharm Oncology, Inc. (ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

BOSTON, Dec. 19, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced its financial results for the first quarter ended March 31, 2020 and provided a corporate update. In our Controlled IL-12 platform for recurrent glioblastoma (rGBM), clinicians and healthcare workers continue to treat patients and facilitate patient enrollment and our anticipated milestones in this program are on track.

BOSTON, May 08, 2020 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a.

Ziopharm Oncology, Inc. (ZIOP), today announced two publications in peer-reviewed scientific journals supporting the Company’s ongoing clinical programs by reinforcing two of the foundational technologies underlying the Company’s approach to the genetic modification of T cells to target cancer. A paper in the journal Blood enhances the clinical data set surrounding the Sleeping Beauty platform by indicating encouraging long-term survival of patients that received CAR-T. The Clinical Cancer Research publication demonstrates that T-cell receptors (TCRs) targeting genetic changes within TP53 can be obtained from T cells in the peripheral blood, overcoming the need to harvest a patient’s tumor. The Company plans to expand its existing library of TCRs as part of its commitment to advance clinical development for the treatment of patients whose solid tumors have driver mutations, including in TP53, using Sleeping Beauty-modified T cells.